

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

022567Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

NDA/Serial Number: 22-567 N000
Drug Name: Vilazodone
Indication: Major depressive disorder
Applicant: PGxHealth
Date(s): Received: March 22, 2010;
PDUFA Due Date: January 22, 2011
Review Priority: Standard
Biometrics Division: Biometrics I, HFD-710
Statistical Reviewer: Phillip Dinh, Ph.D.
Concurring Reviewers: Peiling Yang, Ph.D.
H.M. James Hung, Ph.D.
Medical Division: Division of Psychiatry Products, HFD-130
Clinical Team: Cheri Lindberg M.D., Medical Reviewer, HFD-130
Robert Levin M.D., Medical Team Leader, HFD-130
Project Manager: Bill Bender, HFD-130

Keywords: Clinical studies; NDA review

Table of Contents

1. EXECUTIVE SUMMARY	4
1.1 CONCLUSIONS AND RECOMMENDATIONS	4
1.2 BRIEF OVERVIEW OF CLINICAL STUDIES	4
1.3 STATISTICAL ISSUES AND FINDINGS	4
2. INTRODUCTION	4
2.1 OVERVIEW.....	4
2.2 DATA SOURCES	5
3. STATISTICAL EVALUATION	6
3.1 EVALUATION OF EFFICACY	6
3.1.1 Study CLDA-07-DP-02	6
3.1.1.1 Objectives	6
3.1.1.2 Study Design	6
3.1.1.3 Efficacy Endpoints and Analyses	6
3.1.1.4 Efficacy Results.....	6
3.1.1.4.1 Study Population.....	6
3.1.1.4.2 Sponsor's Efficacy Results for Primary Efficacy Measure	8
3.1.1.4.3 Sponsor's Other Efficacy Results.....	8
3.1.1.4.4 Reviewer's Results and Comments	9
3.1.2 Study GNSC-04-DP-02	11
3.1.2.1 Objective	11
3.1.2.2 Study Design	11
3.1.2.3 Efficacy Endpoints and Analyses	12
3.1.2.4 Efficacy Results.....	12
3.1.2.4.1 Study Population.....	12
3.1.2.4.2 Sponsor's Efficacy Results for the Primary Efficacy Measure.....	13
3.1.2.4.3 Sponsor's Other Efficacy Results.....	14
3.1.2.4.4 Reviewer's Results and Comments	15
3.1.3 Summary of primary efficacy results of phase II studies	17
3.2 EVALUATION OF SAFETY	19
4. FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	19
4.1 GENDER, RACE AND AGE	19
4.1.1 Study CLDA-07-DP-02	19
4.1.1.1 Gender	19
4.1.1.2 Race	19
4.1.1.3 Age	20
4.1.1.4 Baseline disease severity.....	20
4.1.1.5 Disease history.....	21
4.1.2 Study GNSC-04-DP-02	21
4.1.2.1 Gender	21
4.1.2.2 Race	22
4.1.2.3 Age	22
4.1.2.4 Baseline disease severity.....	23
4.1.2.5 Disease history.....	23
5. SUMMARY AND CONCLUSIONS	24
5.1 STATISTICAL ISSUES AND COLLECTIVE EVIDENCE	24
5.2 CONCLUSIONS AND RECOMMENDATIONS	24

LIST OF TABLES

Table 1. Study CLDA-07-DP-02: Disposition of patients.....	7
Table 2. Study CLDA-07-DP-02: Demographic characteristics (Safety sample).....	7
Table 3. Study CLDA-07-DP-02: Sponsor’s primary efficacy results: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample	8
Table 4. Study CLDA-07-DP-02: Sponsor’s efficacy results: change from baseline to week 8 in the CGI-S (LOCF) in the ITT sample.....	8
Table 5. Study CLDA-07-DP-02: Sponsor’s efficacy results: CGI-I at week 8 (LOCF) in the ITT sample	9
Table 6. Study CLDA-07-DP-02: Sponsor’s efficacy results: change from baseline to week 8 in the HAM-D17 (LOCF) in the ITT sample.....	9
Table 7. Study CLDA-07-DP-02: Reviewer’s efficacy analysis: change from baseline in the MADRS total score (MMRM analysis) over time in the ITT sample.....	10
Table 8. Study GNSC-04-DP-02: Disposition of patients.....	12
Table 9. Study GNSC-04-DP-02: Demographic characteristics (Safety sample).....	13
Table 10. Study GNSC-04-DP-02: Sponsor’s primary analysis: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample	13
Table 11. Study GNSC-04-DP-02: Sponsor’s efficacy results: change from baseline to week 8 in the CGI-S (LOCF) in the ITT sample.....	14
Table 12. Study GNSC-04-DP-02: Sponsor’s efficacy results: CGI-I at week 8 (LOCF) in the ITT sample	14
Table 13. Study GNSC-04-DP-02: Sponsor’s efficacy results: change from baseline to week 8 in the HAM-D17 total score (LOCF) in the ITT sample	14
Table 14. Study GNSC-04-DP-02: Reviewer’s efficacy analysis: change from baseline in the MADRS total score (MMRM analysis) over time in the ITT sample.....	15
Table 15. Study GNSC-04-DP-02: Reviewer’s analysis: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample for the first 266 subjects	16
Table 16. Summary of results on the primary efficacy variables of phase II studies	18
Table 17. Study CLDA-07-DP-02: Reviewer’s primary efficacy results by gender: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample	19
Table 18. Study CLDA-07-DP-02: Reviewer’s primary efficacy results by race: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample.....	19
Table 19. Study CLDA-07-DP-02: Reviewer’s primary efficacy results by age: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample.....	20
Table 20. Study CLDA-07-DP-02: Reviewer’s primary efficacy results by baseline disease severity: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample.....	20
Table 21. Study CLDA-07-DP-02: Reviewer’s primary efficacy results by disease history: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample	21
Table 22. Study GNSC-04-DP-02: Reviewer’s primary efficacy results by gender: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample	21
Table 23. Study GNSC-04-DP-02: Reviewer’s primary efficacy results by race: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample.....	22
Table 24. Study GNSC-04-DP-02: Reviewer’s primary efficacy results by age: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample.....	22
Table 25. Study GNSC-04-DP-02: Reviewer’s primary efficacy results by baseline disease severity: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample.....	23
Table 26. Study GNSC-04-DP-02: Reviewer’s primary efficacy results by disease history: change from baseline to week 8 in the MADRS total score (LOCF) in the ITT sample	23

LIST OF FIGURES

Figure 1. Study CLDA-07-DP-02: Cumulative distribution function	11
Figure 2. Study GNSC-04-DP-02: Cumulative distribution function.....	17

1. EXECUTIVE SUMMARY

1.1 Conclusions and Recommendations

Vilazodone at a 40 mg/day was positive in the acute treatment of major depressive disorder, as measured by the change from baseline to week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, based on two pivotal studies.

1.2 Brief Overview of Clinical Studies

This submission contains two pivotal, phase III studies to support the efficacy and safety of vilazodone in the acute treatment of major depressive disorder (MDD). Both studies were randomized, double-blind, placebo-controlled, parallel-group, multicenter, U.S. studies. Both studies investigated the efficacy and safety of vilazodone at a target dose of 40 mg/day. Patients went through a titration period to the target dose. The primary efficacy measure was the change from baseline to week 8 in the MADRS total score.

This NDA also contains five other studies that were either negative or failed and are not subject to this review.

1.3 Statistical Issues and Findings

Both pivotal studies were positive based on the primary efficacy variable pre-specified. None of the secondary efficacy measures were specified as key secondary efficacy measures or agreed upon a priori

(b) (4)

(b) (4)

The long-term efficacy of vilazodone has not been adequately assessed. The current data are based on a one year open-label study (Study CLDA-07-DP-04). Because this was an open-label and there was no control group, the efficacy evaluation is limited and is subject to biases.

(b) (4)

2. INTRODUCTION

2.1 Overview

This review provides a statistical evaluation of the efficacy of vilazodone as an acute treatment of major depressive disorder (MDD).

As defined in the DSM-IV-TR, major depressive disorder (MDD) is a mental illness characterized by one or more major depressive episodes. A major depressive episode implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning. MDD includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.